<DOC>
	<DOCNO>NCT00577278</DOCNO>
	<brief_summary>RATIONALE : Giving monoclonal antibody therapy , radioimmunotherapy , chemotherapy donor stem cell transplant help stop growth cancer cell help stop patient 's immune system reject donor 's stem cell . When stem cell relate donor exactly match patient 's blood , infused patient , may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus sirolimus transplant may stop happen . PURPOSE : This phase II trial study side effect well give indium In 111 ibritumomab tiuxetan yttrium 90 ibritumomab tiuxetan together rituximab , fludarabine , melphalan , donor stem cell transplant work treat patient B-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Yttrium Y 90 Ibritumomab Tiuxetan , Rituximab , Indium In-111 Ibritumomab Tiuxetan , Fludarabine , Melphalan , Donor Stem Cell Transplant Treating Patients With B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety efficacy preparative regimen Yttrium-90 ( 90^Y ) - label anti-cluster differentiation ( CD ) 20 monoclonal antibody ( MAb ) ( yttrium Y 90 ibritumomab tiuxetan ) combination fludarabine ( fludarabine phosphate ) melphalan follow allogeneic hematopoietic stem cell transplant ( APBSCT ) treatment patient B-cell low-grade non-Hodgkin lymphoma ( LG NHL ) , intermediate-grade non-Hodgkin lymphoma ( IG NHL ) mantle cell lymphoma ( MCL ) . II . To evaluate short- long-term complication new preparative regimen , include rate engraftment , acute chronic graft-versus-host-disease ( GVHD ) infectious complication . III . To estimate disease response rate , disease relapse ( progression ) rate , non-relapse mortality rate . IV . To perform exploratory study seek measure/characterize expression costimulatory molecule impact molecule natural killer ( NK ) T cell subset lymphoma patient pre- post- allogeneic stem cell transplant ( ASCT ) stem cell product portion sibling donor . OUTLINE : REDUCED-INTENSITY CONDITIONING : Patients receive rituximab intravenously ( IV ) follow indium In-111 ibritumomab tiuxetan IV 10 minute day -21 rituximab IV follow yttrium Y 90 ibritumomab tiuxetan IV 10 minute day -14 . Patients also receive fludarabine phosphate IV day -9 -5 melphalan IV day -4 . STEM CELL TRANSPLANTATION : Patients undergo APBSCT day 0 . GVHD PROPHYLAXIS : Patients receive tacrolimus IV orally ( PO ) sirolimus PO begin day -3 continue 6 month taper . After completion study treatment , patient follow every 3 month 1 year every 6 month 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>6/6/human leukocyte antigen ( HLA ) match sibling donor relate donor , acceptable match unrelated donor Biopsy ( Bx ) proven diagnosis LG ( include small lymphocytic lymphoma [ SLL ] /chronic lymphocytic leukemia [ CLL ] , lymphoplasmacytic lymphoma , marginal zone , mucosaassociated lymphoid tissue [ MALT ] lymphoma follicular lymphoma [ FL ] grade 1 2 ) , IG ( FL grade 3 DLCL ) MCL NHL Prior demonstrate monoclonal CD20+ malignant BCell population lymph node and/or BM Bx specimen LG NHL ; must relapse achieve complete response ( CR ) partial response ( PR ) prior therapy never respond prior therapy , include chemotherapy and/or MAb therapy MCL NHL disease state Other aggressive Bcell lymphoma ( exclude Burkitt lymphoma Burkittlike lymphoma ) least one relapse refractory chemotherapy Bone marrow ( BM ) aspiration Bx ( = &lt; 42 day prior image dose ) show &lt; 25 % lymphomatous involvement total cellularity ; CLL , peripheral lymphocyte count &lt; 5000/mm^3 Salvage chemotherapy/MAbs reduce BM lymphomatous involvement reduce disease bulk allow Normal renal function test serum creatinine = &lt; 1.5 mg/dl , creatinine clearance &gt; = 60 ml/min Adequate pulmonary function measure forced expiratory volume one second ( FEV1 ) &gt; 65 % predict measured , diffuse capacity carbon monoxide ( DLCO ) &gt; = 50 % predict measured Cardiac Ejection fraction &gt; 50 % Echocardiogram ( ECHO ) multi gate acquisition ( MUGA ) Adequate liver function test bilirubin = &lt; 1.5 x normal serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) = &lt; 2 x normal Negative Human Immunodeficiency Virus ( HIV ) antibody Karnofsky Performance Status ( KPS ) &gt; 80 No active Central Nervous System ( CNS ) disease prior history CNS disease Involved field External Beam Therapy ( EBT ) area exclude lung , heat , liver , kidney allow , evaluated casebycase basis Recovery last therapy therapy dose ( Y90 Zevalin ) must &gt; = 4 week prior systemic chemotherapy DONOR : Age &lt; 75 year DONOR : HLA genotypically identical relate donor acceptable match unrelated donor DONOR : Must consent GCSF administration leukapheresis match sibling donor , unrelated donor , donor sign standard consent donation designate donor collection center DONOR : Must adequate vein leukapheresis agree placement Central Venous Catheter ( CVC [ femoral , subclavian ] ) Presence Human AntiZevalin Antibody ( HAZA ) Prior radioimmunotherapy ( RIT ) Prior AHSCT ; prior aHSCT allow ; prior fractionate total body irradiation ( FTBI ) condition regimen evaluate individual basis Prior malignancy , except : adequately treat basal cell squamous cell skin cancer ; adequately treat noninvasive carcinoma ; cancer patient diseasefree least 5 year ; myelodysplastic syndrome ( MDS ) exclude criterion Active evidence Hepatitis B C infection ; hepatitis B surface antigen positive Total peripheral lymphocyte count &gt; 5,000/mm^3 SLL/CLL Burkitt lymphoma Burkittlike lymphoma DONOR : Age &lt; 12 year DONOR : Identical twin DONOR : Pregnancy DONOR : HIV infection DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness disease may preclude use GCSF ( eg , recent thromboembolic event ) ; unrelated donor , consider ineligible National Marrow Donor Program ( NMDP ) donor evaluation center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>